Results
800
Companies which are more than 50% undervalued based on analyst price target.
800 companies
Daiichi Sankyo Company
Market Cap: JP¥7.0t
Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally.
4568
JP¥3,732.00
7D
10.2%
1Y
-31.2%
Summit Therapeutics
Market Cap: US$17.8b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$24.39
7D
-0.9%
1Y
455.6%
ALTEOGEN
Market Cap: ₩17.4t
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
A196170
₩326,000.00
7D
-2.7%
1Y
69.5%
BioMarin Pharmaceutical
Market Cap: US$11.4b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$59.93
7D
0.3%
1Y
-22.5%
Trulieve Cannabis
Market Cap: CA$15.5b
Operates as a cannabis retailer.
TRUL
CA$6.23
7D
-1.7%
1Y
-60.7%
Moderna
Market Cap: US$10.2b
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
MRNA
US$27.99
7D
9.8%
1Y
-80.5%
Corcept Therapeutics
Market Cap: US$7.9b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$76.22
7D
8.0%
1Y
164.7%
Roivant Sciences
Market Cap: US$7.7b
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
ROIV
US$11.04
7D
2.6%
1Y
-1.7%
Revolution Medicines
Market Cap: US$7.4b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$40.47
7D
1.3%
1Y
2.0%
Jazz Pharmaceuticals
Market Cap: US$6.8b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$111.02
7D
7.9%
1Y
3.8%
Chongqing Zhifei Biological Products
Market Cap: CN¥47.6b
Chongqing Zhifei Biological Products Co., Ltd.
300122
CN¥19.88
7D
1.4%
1Y
-43.3%
Grifols
Market Cap: €5.8b
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
GRF
€9.53
7D
10.5%
1Y
2.8%
BridgeBio Pharma
Market Cap: US$6.4b
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
BBIO
US$33.71
7D
1.4%
1Y
15.1%
Ionis Pharmaceuticals
Market Cap: US$5.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$34.47
7D
6.0%
1Y
-7.8%
Legend Biotech
Market Cap: US$5.4b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$30.07
7D
-3.2%
1Y
-30.0%
Axsome Therapeutics
Market Cap: US$5.3b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$108.35
7D
2.5%
1Y
38.7%
Beijing Tiantan Biological Products
Market Cap: CN¥38.0b
Beijing Tiantan Biological Products Co., Ltd.
600161
CN¥19.23
7D
0.5%
1Y
-18.5%
Zealand Pharma
Market Cap: DKK 29.8b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 430.20
7D
5.5%
1Y
-29.9%
Vaxcyte
Market Cap: US$4.1b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$36.57
7D
21.7%
1Y
-50.3%
Krystal Biotech
Market Cap: US$3.8b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$131.55
7D
-2.2%
1Y
-21.2%
Sarepta Therapeutics
Market Cap: US$3.7b
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
SRPT
US$39.99
7D
10.5%
1Y
-69.0%
Cytokinetics
Market Cap: US$3.7b
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States.
CYTK
US$32.66
7D
6.7%
1Y
-45.7%
Avidity Biosciences
Market Cap: US$3.6b
A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
RNA
US$31.64
7D
5.9%
1Y
7.2%
Zai Lab
Market Cap: US$3.6b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$32.63
7D
14.0%
1Y
63.1%
Dottikon ES Holding
Market Cap: CHF 2.9b
Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide.
DESN
CHF 211.00
7D
3.4%
1Y
-18.5%
Ultragenyx Pharmaceutical
Market Cap: US$3.4b
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
RARE
US$37.35
7D
5.5%
1Y
-8.0%
CRISPR Therapeutics
Market Cap: US$3.3b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$39.25
7D
5.5%
1Y
-28.3%
Arcellx
Market Cap: US$3.2b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$60.54
7D
3.9%
1Y
13.6%
Viking Therapeutics
Market Cap: US$3.1b
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
VKTX
US$28.67
7D
3.4%
1Y
-55.4%
Laboratorios Farmaceuticos Rovi
Market Cap: €2.7b
Manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally.
ROVI
€52.80
7D
0%
1Y
-40.6%
Merus
Market Cap: US$3.0b
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
MRUS
US$44.01
7D
8.9%
1Y
1.4%
Metsera
Market Cap: US$3.0b
A clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
MTSR
US$29.25
7D
12.1%
1Y
n/a
Akero Therapeutics
Market Cap: US$3.0b
Engages in the development of treatments for patients with serious metabolic diseases in the United States.
AKRO
US$47.57
7D
18.9%
1Y
135.0%
Alvotech
Market Cap: US$3.0b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$9.78
7D
-7.4%
1Y
-29.8%
Genscript Biotech
Market Cap: HK$23.7b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$10.94
7D
3.8%
1Y
-4.0%
Crinetics Pharmaceuticals
Market Cap: US$2.9b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$31.37
7D
1.4%
1Y
-36.6%